Filing Flows › Editas Medicine (EDIT) › Q1 2026 › vs Q4 2025
Editas Medicine (EDIT) Q1 2026 vs Q4 2025 (quarter over quarter)
Editas Medicine's revenue fell $21.9M (-89%) from $24.7M in Q4 2025 to $2.8M in Q1 2026.
Editas Medicine, Q1 2026: revenue $2.8M (-39% year over year), operating margin -883.2%, net loss $25.0M, operating cash flow −$23.1M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.8M | $24.7M | −$21.9M | -89% |
| Other income, net | $21K | $2.1M | −$2.1M | -99% |
| Net loss | $25.0M | $5.6M | $19.4M | +345% |
| Costs & expenses | $27.8M | $32.5M | −$4.7M | -14% |
| Operating costs | $27.8M | $32.5M | −$4.7M | -14% |
| Operating cash sources | $25.6M | $39.3M | −$13.7M | -35% |
| Depreciation | $483K | $805K | −$322K | -40% |
| Share-based compensation | $2.1M | $2.1M | −$27K | -1% |
| Cash used in operations | $23.1M | $36.4M | −$13.3M | -37% |
| Net loss absorbed | $25.0M | $5.6M | $19.4M | +345% |
| Working capital & other | $664K | $33.7M | −$33.0M | -98% |
Questions
How much did Editas Medicine's revenue grow quarter over quarter in Q1 2026?
Editas Medicine's revenue fell $21.9M (-89%) from $24.7M in Q4 2025 to $2.8M in Q1 2026.